Creditos
Bus.Valor
Conectar
Bus.User
Desde:
23/03/2010
OFF:
6 Min
https://www.cnmv.es/portal/consultas/EE/PosicionesCortas.aspx?nif=A-78267176
0
Mensaje de: Javi72 Hora: 11/03/2024 18:19:56
Habrá hito, lo que no se es si será grande o pequeño.
Habrá hito, lo que no se es si será grande o pequeño.
Por el ojhito! Como hasta ahora.
(1)
5
Zepzelca (lurbinectedin):
Zepzelca net product sales increased 7% to $289.5 million in 2023 and increased 3% to $74.0 million in 4Q23 compared to the same periods in 2022.
Enrollment in the Phase 3 trial evaluating first-line (1L) use of Zepzelca in combination with Tecentriq® (atezolizumab) in small cell lung cancer, in partnership with Roche, is complete; expect top-line progression-free survival (PFS) data readout at the end of 2024 or early 2025.
Zepzelca net product sales increased 7% to $289.5 million in 2023 and increased 3% to $74.0 million in 4Q23 compared to the same periods in 2022.
Enrollment in the Phase 3 trial evaluating first-line (1L) use of Zepzelca in combination with Tecentriq® (atezolizumab) in small cell lung cancer, in partnership with Roche, is complete; expect top-line progression-free survival (PFS) data readout at the end of 2024 or early 2025.
(1)
0
Mostrar mas Mensajes
